MC2 Therapeutics launches psoriasis cream in US

The pharmaceutical firm has worked with partner Epi Health to launch Wynzora on the US market, where it was authorized as a treatment for psoriasis last year.

Jesper J. Lange, CEO of MC2 Therapeutics | Photo: MC2 Therapeutics/PR

Just under a year after MC2 Therapeutics received approval from the FDA for its psoriasis cream Wynzora, the treatment has been launched on the US market, the company reports in a press release.

The launch has been planned in collaboration with partner Epi Health, which specializes in dermatology, though MC2 has been working to establish itself as an independent company in the US.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Pfizer upgrades guidance for sales of covid-19 vaccine

The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.

Further reading

Related articles

Trial banner

Latest news

See all jobs